Nominated Adviser Status

RNS Number : 0079K

Evgen Pharma PLC

10 December 2018

 

10 December 2018

Evgen Pharma plc

("Evgen" or the "Company")

Nominated Adviser Status

The directors are aware of the proposed merger of its nominated adviser, Northland Capital Partners Limited ("Northland") with SP Angel Corporate Finance LLP ("SP Angel").  The directors have also been informed that Northland has voluntarily agreed to relinquish its nominated adviser status and will be removed from the register of nominated advisers with effect from 7.00 a.m. on 1 February 2019.

The Company is currently in discussions with alternative nominated advisers and is confident that a suitable replacement will be appointed in January 2019.

In accordance with AIM Rule 1, in the unlikely event that the Company fails to appoint a new nominated adviser by 1 February 2019, the Exchange will suspend trading in the Company's AIM Securities.  If the Company has failed to appoint a replacement nominated adviser by 4 March 2019 the admission of its AIM Securities will be cancelled. 

Enquiries:

Evgen Pharma plc	c/o [phone]
Dr Stephen Franklin, CEO
Richard Moulson, CFO
Buchanan Mark Court, Sophie Wills, Tilly Abraham	[phone]
Northland Capital Partners Limited Matthew Johnson, Gerry Beaney (Corporate Finance) Rob Rees (Corporate Broking)	[phone]
WG Partners LLP Nigel Barnes, Claes Spång	[phone]

Notes for editors:

About Evgen Pharma plc

Evgen is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke.  The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane.  The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin. 

Evgen commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office at the Liverpool Science Park, Liverpool.  It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG. 

For further information, please visit: www.evgen.com

For commissioned research on the Company, please visit: http://evgen.com/investors/analyst-coverage/ 

 

END

 

 

MSCTMBITMBABBJP